Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1093/eurheartj/ehs092 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) |
| https://doi.org/10.1093/eurheartj/ehw106 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice |
| https://doi.org/10.1093/eurheartj/ehab484 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice |
| https://doi.org/10.1093/eurheartj/ehm316 | European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) |
| https://doi.org/10.1093/eurheartj/ehx144 | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel |
| https://doi.org/10.1016/s0140-6736(23)02750-2 | Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults |
| https://doi.org/10.1097/01.hjr.0000277983.23934.c9 | Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) |
| https://doi.org/10.1177/2047487316653709 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice |
| https://doi.org/10.1093/eurheartj/ehac361 | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement |
| https://doi.org/10.1161/circulationaha..107.181425 | ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain |
| https://doi.org/10.1093/eurheartj/ehab551 | Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society |
| https://doi.org/10.1093/eurjpc/zwab154 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice |
| https://doi.org/10.1016/j.atherosclerosis.2016.05.037 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice |
| https://doi.org/10.1161/cir.0b013e3181d4b618 | ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography |
| https://doi.org/10.1093/eurheartj/ehy182 | Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract |
| https://doi.org/10.1007/s12529-012-9242-5 | European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) |
| https://doi.org/10.1093/eurheartj/ehad197 | 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance |
| https://doi.org/10.1016/s0140-6736(21)01122-3 | Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) |
| https://doi.org/10.5114/aoms.2017.69326 | Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel |
| https://doi.org/10.1093/nutrit/nux047 | Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel |
| https://doi.org/10.1097/01.hjr.0000277984.31558.c4 | Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) |
| https://doi.org/10.1160/th11-10-0690 | Bleeding risk assessment and management in atrial fibrillation patients |
| https://doi.org/10.1097/00149831-200312001-00001 | European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) |
| https://doi.org/10.1001/jamacardio.2019.5173 | Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia |
| https://doi.org/10.1093/eurheartj/ehx549 | 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia |
| https://doi.org/10.1093/eurheartj/ehad472 | Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society |
| https://doi.org/10.1016/s2213-8587(19)30264-5 | Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement |
| https://doi.org/10.1016/j.rec.2016.09.009 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice |
| https://doi.org/10.1016/j.atherosclerosis.2021.03.039 | Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force |
| https://doi.org/10.1016/j.atherosclerosis.2023.04.012 | Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society |
| https://doi.org/10.1714/2729.27821 | Linee guida europee 2016 sulla prevenzione delle malattie cardiovascolari nella pratica clinica. Sesta Task Force congiunta della Società Europea di Cardiologia e di altre Società sulla Prevenzione delle Malattie Cardiovascolari nella Pratica Clinica (costituita da rappresentanti di 10 società e da esperti invitati). Redatte con il contributo straordinario dell’Associazione Europea per la Prevenzione e Riabilitazione Cardiovascolare (EACPR) |
| https://doi.org/10.1016/j.atherosclerosis.2025.119218 | The Brussels International Declaration on Lipoprotein(a) Testing and Management |
| https://doi.org/10.1136/gutjnl-2024-332602 | Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism |
| https://doi.org/10.1016/j.jacc.2011.10.860 | 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease |
| https://doi.org/10.1002/ccd.22495 | ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography |
| https://doi.org/10.1161/cir.0b013e3182031a3c | ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 Performance Measures for Adults With Peripheral Artery Disease |
| https://doi.org/10.1016/j.atherosclerosis.2013.05.019 | Gut microbiota: An environmental risk factor for cardiovascular disease |
| https://doi.org/10.15829/1560-4071-2017-5-7-77 | 2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS |
| https://doi.org/10.3205/hta000136 | The time is now: Achieving FH paediatric screening across Europe – The Prague Declaration |
| https://doi.org/10.1016/j.repce.2013.07.001 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) |
| https://doi.org/10.1373/clinchem.2015.247866 | Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come? |
| https://doi.org/10.1016/j.atherosclerosis.2019.03.004 | Triglycerides and cardiovascular risk: Apolipoprotein B holds the key |
| https://doi.org/10.1016/j.atherosclerosis.2020.09.023 | DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe |
| https://doi.org/10.1016/j.atherosclerosis.2015.06.049 | Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group |
| https://doi.org/10.1016/j.arteri.2013.09.004 | International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia |
| https://doi.org/10.1016/j.atherosclerosis.2019.09.015 | First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated |
| https://doi.org/10.1093/eurheartj/ehy147 | New prospects for PCSK9 inhibition? |
| https://doi.org/10.1016/j.cmi.2022.08.028 | Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohort |
| https://doi.org/10.1093/eurheartj/ehae791 | Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry |
| https://doi.org/10.1186/s12944-020-01265-z | Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey |
| https://doi.org/10.3389/fgene.2021.693952 | The Role of the European Society of Human Genetics in Delivering Genomic Education |
| https://doi.org/10.1016/j.atherosclerosis.2020.03.013 | Targeting LDL cholesterol: Early treatment is key to population health |
| https://doi.org/10.1016/j.atherosclerosis.2025.120403 | The essential role of sex and gender in atherosclerosis research: A statement from the Editorial Board of Atherosclerosis and Executive Committee of the European Atherosclerosis Society |
| https://doi.org/10.1016/j.atherosclerosis.2014.07.030 | Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men |
| https://doi.org/10.1177/1358863x10390838 | ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease |
| https://doi.org/10.5334/gh.1077 | Preventing the Next Pandemic: The Case for Investing in Circulatory Health – A Global Coalition for Circulatory Health Position Paper |
| https://doi.org/10.1016/j.atherosclerosis.2013.08.035 | New EAS Consensus Statement on FH: Improving the care of FH patients |
| https://doi.org/10.1016/j.atherosclerosis.2011.11.030 | The emerging role of lipidomics |
| https://doi.org/10.1016/j.atherosclerosis.2017.12.031 | The challenge of peripheral arterial disease: How do we improve outcome? |
| https://doi.org/10.1016/j.atherosclerosis.2014.01.047 | Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods |
| https://doi.org/10.1016/j.atherosclerosis.2017.12.032 | Update on SAMS: Statin-associated muscle symptoms |
| https://doi.org/10.1016/j.atherosclerosis.2013.11.050 | Improving the care of high-risk patients: The potential of PCSK9 |
| https://doi.org/10.1016/j.atherosclerosis.2015.06.050 | EAS Consensus Panel statement on homozygous FH |
| https://doi.org/10.1016/j.atherosclerosis.2020.11.029 | Should we treat high LDL cholesterol in ‘healthy’ elderly individuals? |
| https://doi.org/10.1016/j.athplu.2024.10.002 | A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA) |
| https://doi.org/10.1016/j.msea.2021.141099 | The mechanical property evolution and grain boundary accommodation during hydride transformation in commercial pure titanium |
| https://doi.org/10.5551/jat.44677 | Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes |
| https://doi.org/10.1016/j.diabet.2021.101265 | Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease |
| https://doi.org/10.1016/j.atherosclerosis.2015.06.021 | Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel |
| https://doi.org/10.1016/j.atherosclerosis.2011.06.025 | Importance of HDL functionality to cardiovascular risk |
| https://doi.org/10.1016/j.repc.2013.06.001 | Recomendações Europeias para a prevenção da doença cardiovascular na prática clínica (versão de 2012) |
| https://doi.org/10.1016/j.atherosclerosis.2019.09.013 | News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published |
| https://doi.org/10.1016/j.atherosclerosis.2018.08.037 | New joint consensus initiative on quantifying atherogenic lipoproteins |
| https://doi.org/10.1016/j.atherosclerosis.2021.11.015 | Joint statement from the European Atherosclerosis Society and European Society of Vascular Medicine focuses on patients with peripheral arterial disease |
| https://doi.org/10.1016/j.atherosclerosis.2020.06.026 | Familial hypercholesterolemia: An urgent public health priority |
| https://doi.org/10.1016/j.atherosclerosis.2021.05.013 | EAS Task Force gives practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients |
| https://doi.org/10.1016/j.atherosclerosis.2021.03.005 | Reply to: “It's time to stop the nonsense of withholding lipid lowering therapy on account of age” and “The evidence around safe and effective LDL cholesterol-lowering therapy in elderly individuals demands validity and clinical relevance” |
| https://doi.org/10.1177/1358863x07084714 | ACCF/AHA 2007 Clinical Competence Statement on vascular imaging with computed tomography and magnetic resonance |
| https://doi.org/10.1016/j.atherosclerosis.2011.05.027 | Mediterranean diet for combating the metabolic syndrome |
| https://doi.org/10.1016/j.atherosclerosis.2011.10.008 | CETP inhibition in perspective |
| Europejskie wytyczne dotyczace zapobiegania chorobom serca i naczyń w praktyce klinicznej na 2012 rok | |
| https://doi.org/10.1016/j.atherosclerosis.2018.10.009 | Cholesterol and inflammatory risk: Insights from secondary and primary prevention |
| https://doi.org/10.1016/j.atherosclerosis.2020.08.019 | Residual inflammatory risk: Lessons from trials for the future |
| https://doi.org/10.1016/s0735-1097(21)02769-8 | PRESENCE AND BURDEN OF CORONARY ATHEROSCLEROSIS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| https://doi.org/10.1038/s41431-021-01019-0 | The Young Geneticists Network and the ESHG-Young committee, a forward-looking international community |
| https://doi.org/10.1016/j.atherosclerosis.2011.09.042 | News from the literature: Focus on joint ESC/EAS dyslipidemia guidelines |
| https://doi.org/10.1016/j.atherosclerosis.2013.03.011 | Triglyceride-rich lipoproteins and HDL: What do recent trials tell us? |
| https://doi.org/10.1016/j.atherosclerosis.2011.12.036 | Controversies in dyslipidaemia management |
| https://doi.org/10.1016/j.atherosclerosis.2019.06.913 | Highlights from the 87th EAS congress, 26–29th May 2019 |
| https://doi.org/10.1016/j.jadohealth.2020.12.060 | 51. Clinical Presentation and Quality of Life Burden Associated With Hyperhidrosis in Children and Adolescents |
| https://doi.org/10.1016/j.atherosclerosis.2021.02.005 | SAMSON, SAMS and nocebo effects |
| https://doi.org/10.1016/j.atherosclerosis.2021.03.027 | Latest European Atherosclerosis Society statement reaffirms commitment to the UN Sustainable Development Goals 2030 Agenda |
| https://doi.org/10.1016/j.jacl.2021.04.012 | From the President of the International Atherosclerosis Society: The Iraqi Lipid Clinics Network |
| https://doi.org/10.1016/j.atherosclerosis.2022.02.008 | Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed |
| https://doi.org/10.20996/1819-6446-2008-4-4-90-107 | EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (ENDING). FOURTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE |
| https://doi.org/10.1016/j.atherosclerosis.2019.12.012 | Commentary on rare dyslipidaemia paper |
| https://doi.org/10.1097/01.hjr.0000087913.96265.e2 | European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). |
| https://doi.org/10.1590/s0066-782x2000001000004 | PANDORA - Survey of Brazilian cardiologists about cholesterol reduction |
| https://doi.org/10.1016/j.atherosclerosis.2015.06.039 | Highlights of the 83rd European Atherosclerosis Society (EAS) annual Congress, Glasgow 22–25 March, 2015 |
| https://doi.org/10.1016/j.atherosclerosis.2011.07.014 | New studies in atherosclerosis research |